Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
1(25.0%)
N/A
1(25.0%)
4Total
Phase 1(2)
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07470996Recruiting

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR

Role: collaborator

NCT07370116Phase 2Not Yet Recruiting

Omitting Nasogastric Tube Decompression in Minimally Invasive Pancreaticoduodenectomy

Role: collaborator

NCT07363967Phase 1Recruiting

A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors

Role: collaborator

NCT06541639Phase 1Recruiting

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

Role: collaborator

NCT01658930Not ApplicableCompleted

Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

Role: collaborator

All 5 trials loaded